Larimar study backs skin frataxin as surrogate endpoint for nomlabofusp trials

• Larimar Therapeutics published cross-species preclinical findings plus clinical patient data supporting skin sampling as a surrogate to track frataxin changes for its Friedreich’s ataxia drug candidate, nomlabofusp.
• Results have already been presented via online publication in Clinical and Translational Science.
• Study showed nomlabofusp raised frataxin in disease-relevant organs, with changes tracking levels measured in more accessible tissues such as skin or buccal cells.
• Data package has been reviewed by FDA to support potential use of skin frataxin as a reasonably likely surrogate endpoint for a registrational program under accelerated approval.
• Larimar reiterated plans to submit a Biologics License Application in June 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604301605PRIMZONEFULLFEED9710925) on April 30, 2026, and is solely responsible for the information contained therein.